REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation

JAMA Neurology Publishes Complete Results of Positive Phase 3

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

FDA Approves First Drug to Treat Agitation Symptoms Associated

Otsuka, Lundbeck's sNDA for Rexulti received US FDA approval

First-Ever Drug for Alzheimer's Agitation, Brexpiprazole, Nears

Lundbeck, Otsuka drug cut agitation in Alzheimer's patients